Caxton Associates LLP Invests $729,000 in Axsome Therapeutics, Inc. $AXSM

Caxton Associates LLP acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,311 shares of the company’s stock, valued at approximately $729,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AXSM. Birchview Capital LP grew its stake in Axsome Therapeutics by 1.0% during the 4th quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock worth $1,107,000 after purchasing an additional 61 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Axsome Therapeutics by 3.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,921 shares of the company’s stock valued at $351,000 after purchasing an additional 65 shares in the last quarter. Xponance LLC raised its position in Axsome Therapeutics by 2.4% in the 4th quarter. Xponance LLC now owns 3,265 shares of the company’s stock valued at $596,000 after purchasing an additional 76 shares in the last quarter. Assetmark Inc. raised its position in Axsome Therapeutics by 7.2% in the 1st quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock valued at $200,000 after purchasing an additional 79 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Axsome Therapeutics by 4.2% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 2,190 shares of the company’s stock valued at $400,000 after buying an additional 89 shares during the period. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on AXSM shares. Oppenheimer set a $280.00 price objective on Axsome Therapeutics in a research report on Monday, May 4th. Royal Bank Of Canada raised their target price on shares of Axsome Therapeutics from $302.00 to $304.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 price target on shares of Axsome Therapeutics in a research note on Thursday, June 11th. Needham & Company LLC boosted their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, BMO Capital Markets initiated coverage on shares of Axsome Therapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $261.48.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $241.00 on Monday. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. Axsome Therapeutics, Inc. has a fifty-two week low of $96.09 and a fifty-two week high of $260.19. The firm has a market capitalization of $12.40 billion, a PE ratio of -64.61 and a beta of 0.60. The stock’s 50-day simple moving average is $239.25 and its 200-day simple moving average is $200.80.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The business had revenue of $191.20 million for the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business’s revenue for the quarter was up 57.4% compared to the same quarter last year. As a group, equities research analysts forecast that Axsome Therapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 49,666 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $240.25, for a total value of $11,932,256.50. Following the completion of the transaction, the chief executive officer owned 7,229 shares in the company, valued at $1,736,767.25. This represents a 87.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Roger Jeffs sold 286 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total value of $70,407.48. Following the completion of the sale, the director directly owned 58,653 shares of the company’s stock, valued at $14,439,195.54. The trade was a 0.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 155,852 shares of company stock valued at $37,230,112 in the last quarter. Company insiders own 20.60% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.